רÀûÃû³Æ£º¼ì²âÈËȫѪÖÐËû¿ËĪ˾ҩÎïŨ¶ÈµÄ»¯Ñ§·¢¹âøÁªÃâÒßÊÔ¼ÁºÐµÄÖÆ×÷·½·¨
¼¼ÊõÁìÓò£º
±¾·¢Ã÷Éæ¼°Ò½Ñ§¼ì²â¼¼Êõ£¬ÌرðÊÇÒ»ÖÖÓÃÓÚÈËȫѪÖÐËû¿ËĪ˾ҩÎïŨ¶ÈµÄ¼ì²âÊÔ¼ÁºÐ¡£
±³¾°¼¼Êõ£º
Ëû¿ËĪ˾(tacrolimus)ÊÇÓÉFujisawa¹«Ë¾1984·¢ÏÖµÄÒ»Àà´ó»·ÄÚõ¥ÀàÃâÒßÒÖÖÆ¼Á£¬ÓÚ1989ÄêÊ×´ÎÓ¦ÓÃÓÚÁÙ´²£¬ÏÖÔÚÒѾ±»¹ã·ºÓ¦ÓÃÓÚÒÆÖ²ºóµÄÅųâÖÎÁÆ¡£Æä×÷ÓûúÀíÊÇ£¬Ëû¿ËĪ˾ÓëÆä½áºÏµ°°×FKBP12Ïà½áºÏºóÒÖÖÆÁËÁ×ËáøµÄ»îÐÔ£¬´Ó¶øÒÖÖÆºËµ÷µ°°×ºÍT ϸ°û»î»¯Òò×Ó(Èç°×½éËØ_2)¡¢Ô°©»ùÒòºÍϸ°ûÒò×ÓÏàÓ¦ÊÜÌå(Èç°×½éËØ-2ÊÜÌå)µÄ±í´ï¡£µ«Êµ¼ÊÇé¿öÊÇ£¬Ëû¿ËĪ˾µÄ¸öÌåÎüÊÕÂʺÍÇå³ýÂʲî±ðºÜ´ó£¬ÇÒÓÃÒ©¼ÁÁ¿ÓëѪҩŨ¶ÈÖ®¼äȱ·¦½ôÃܵÄÏà¹ØÐÔ£¬ÔÚ¸ßѪŨ¶ÈʱÓÐÒ»¶¨µÄ¶¾ÐÔ£¬Ö÷ÒªÊÇÉñ¾¶¾ÐÔ¡¢Éö¶¾ÐÔºÍÌÇ´úлÒì³£µÈ¡£ÓÉÓÚËû¿ËĪ˾µÄÖÎÁÆ´°·¶Î§½ÏÕ£¬¸øÁÙ´²ÖÎÁÆÔö¼ÓÁËÏ൱´óµÄÄѶȣ¬Òò´ËÐèÒª·´¸´²â¶¨ÆÚѪÖÐŨ¶ÈÒÔµ÷ÕûÓÃÒ©¼ÁÁ¿¡£¾ÝÏà¹ØÊý¾Ýͳ¼Æ£¬½ØÖÁ2008Ä꣬ÎÒ¹úÒÆÖ²ÊÖÊõ×ÜÁ¿ÒѾ³¬¹ý10Íò´Î£¬ÏÖÔÚÎÒ¹úÒѾ³ÉΪ¼ÌÃÀ¹úÖ®ºóµÄÊÀ½çµÚ¶þ´óÆ÷¹ÙÒÆÖ²¹ú¼Ò£¬Ã¿ÄêÆ÷¹ÙÒÆÖ²ÊÖÊõÒѾ³¬¹ý1ÍòÀý£¬¶øÇÒËæ×ž¼Ã¼°Ò½ÁÆË®Æ½µÄ·¢Õ¹£¬ÒÔºóµÄÆ÷¹ÙÒÆÖ²»¼Õß»áÔ½À´Ô½¶à¡£Ëû¿ËĪ˾ËäÈ»½Ï»·æßÃ¹ËØ AÉÏÊÐÍí£¬µ«ÆäҩЧ¸üΪÃ÷ÏÔ£¬ÊÇ»·æßÃ¹ËØÀàÃâÒßÒÖÖÆ¼ÁµÄ50-100±¶£¬²¢ÇÒ¾ßÓÐÌá¸ßÒÆÖ²Éú´æÂÊ¡¢½µµÍ¼±ÐÔÅųⷴӦ·¢ÉúÂÊ¡¢½µµÍ¸ÐȾÂÊ¡¢¶ÔÀà¹Ì´¼ÎÞÏà¶ÔÒÀÀµÐÔ¼°¸±×÷ÓýÏÉÙµÈÌØµã£¬ÏÖÔÚÊǵ±Ç°¾ÓÓÚÊг¡Ç°¼¸Î»µÄÃâÒßÒÖÖÆ¼Á£¬Ô¼Õ¼µ±Ç°ÃâÒßÒÖÖÆ¼ÁÊг¡·Ý¶îµÄ10%×óÓÒ¡£ ÏÖÔÚ¹úÄÚÊг¡ÉÏÓÃÓÚËû¿ËĪ˾¼ì²âµÄÊÔ¼ÁºÐ¼¸ºõÈ«²¿ÒÀÀµ½ø¿Ú£¬¶øÕâЩ½ø¿ÚÊÔ¼ÁºÐÈ«²¿Óñ¾¹«Ë¾ÅäÌ׵ķÖÎöÒÇÆ÷½øÐмì²â£¬ÕâÑù¾ÍÌá¸ßÁËÒ½Ôº¼°¼ì²âÖÐÐĵÄ×¼ÈëÃż÷£¬¶Ô¼ì²âʵÑé²Ù×÷ÈËÔ±ÒªÇóÒ²±È½Ï¸ß£¬Í¬Ñù¸½¼ÓÓÚ²¡È˵ÄÕïÁÆ·ÑÓÃÒ²ÏàÓ¦Ìá¸ß¡£µ«Êµ¼ÊÇé¿öÊÇ£¬ÏÖÔÚÎÒ¹úÈ˾ù¹úÃñ¾¼ÃˮƽƫµÍ£¬Ò½ÁÆÎÀÉú¼ì²â»ú¹¹Ë®Æ½²î¾à·Ç³£´ó£¬Æ÷¹ÙÒÆÖ²²¡È˵ÄÒ½ÁƸºµ£ºÜÖØ£¬ºÜ¶àµØ·½Ò½Ôº¼°¼ì²âÖÐÐÄûÓÐÄÜÁ¦¹ºÂò°º¹óµÄÒ½ÁƼì²âÉ豸¡£ÕâÑù£¬Êг¡¸üÐèÒª²Ù×÷·½±ã¼ò½Ý£¬ÄܽÚÔ¼²¡ÈË¡¢Ò½Ôº¾¼Ã³É±¾ÇÒÖÊÁ¿Îȶ¨¿É¿¿ÄÜ´ïµ½¼ì²âÒªÇóµÄÊʺÏÖйúÏÖÓйúÇéµÄ¼ì²âÊÔ¼ÁºÐ¡£Îª´ïµ½¸öÌ廯¸øÒ©·½°¸£¬±ÜÃâ¶¾¸±·´Ó¦ºÍÅųⷴӦµÄ·¢Éú£¬Ö»ÄÜÔÚÓÐÌõ¼þµÄÒ½Ôº²ÅÄܽ«¼à²âÆäѪҩŨ¶È×÷Ϊ³£¹æ¹¤×÷£¬Ä¿Ç°²â¶¨È«ÑªÖÐËû¿ËĪ˾Ũ¶ÈµÄ·½·¨Ö÷ÒªÓÐÁ½´óÀà¸ßЧҺÏàÉ«Æ×·¨ºÍÃâÒß±ê¼Ç·ÖÎö·¨¡£¸ßЧҺÏàÉ«Æ×·¨ÊÇ70Äê´ú·¢Õ¹ÆðÀ´µÄÒ»ÖֲⶨѪҩŨ¶ÈµÄÎïÀí·½·¨£¬²ÉÓÃÌØÊâ×°ÖõÄÖùÉ«Æ×·¨£¬ÀûÓÃͬһÖÖÎü¸½¼Á¶Ô²»Í¬ÎïÖÊÎü¸½ÄÜÁ¦µÄ²î±ð½øÐзÖÀë¼ø¶¨£¬ÆäÌØÒìÐԸߣ¬Ö»²â¶¨Ëû¿ËĪ˾ĸҩµÄŨ¶È¶ø²»²â¶¨Æä´úлÎïµÄŨ¶È£¬½á¹û׼ȷ¿É¿¿£¬µ«ÆäÑù±¾Ç°´¦Àí²Ù×÷·±Ëö£¬ÇÒÐèÌØÊâµÄ¼¼ÊõºÍ°º¹óµÄÉ豸ÒÔ¼°¸ßËØÖʵÄרҵ¼¼Ê¦½øÐвÙ×÷£¬Ò»¶¨³Ì¶ÈÉÏ·Á°ÆäÉîÈ뿪չºÍÆÕ¼°¡£ÃâÒß±ê¼Ç·ÖÎö·¨ÊÇÒÔ¿¹Ô»ò°ë¿¹ÔÓ뿹ÌåÖ®¼äÌØÒìÐÔÇ׺ͷ´Ó¦Îª»ù´¡µÄÃâÒß±ê¼Ç¼¼ÊõĿǰÓÃÓڲⶨѪҩŨ¶ÈµÄÃâÒß·ÖÎö·¨³£Óõıê¼ÇÎïÓзÅÉäÐÔºËËØ¡¢Ó«¹â¼ÁºÍøÈý´óÀ࣬Æä²â¶¨¼¼Êõ·Ö±ð³ÆÎª·ÅÉäÃâÒß·ÖÎö·¨(Radioimmunoassay£¬RIA)¡¢Ó«¹âÃâÒß·ÖÎö·¨ (Fluoroimmunoassay, FPIA)ºÌ¿ÚøÃâ·ÖÎö·¨(Enzyme immunoassay, EIA)¡£ËûÃǹ²Í¬µÄÓŵãÊÇÌØÒìÐÔÇ¿¡¢ÁéÃô¶ÈºÍ¾«Ãܶȸߡ¢×¼È·ÐԺᢼò±ã¡¢¿ìËÙ£¬Ò×ʵÏÖ×Ô¶¯»¯£¬ÊÊÓÃÓÚ³£¹æºÍ¼±Õ﹤×÷¡£·ÅÉäÃâÒ߲ⶨ·¨ËäÈ»¾ßÓиßÁéÃô¶È¡¢¸ßÌØÒìÐÔµÄÓŵ㣬µ«Æä²Ù×÷²½Öè½Ï¶à£¬ÐèÒªÌØÊâµÄ¼ì²âÉ豸£¬²¢ÇÒʹ²Ù×÷ÈËÔ±Êܵ½·ÅÉäÐÔΣº¦£¬Í¬Ê±ÊÔ¼ÁºÐµÄʹÓÃÆÚÏÞÒ²»áÊܱê¼ÇµÄ·ÅÉäÐÔÎïÖʵÄË¥±äÆÚµÄÏÞÖÆ£¬¹Ê½üÄêÀ´Ðí¶à±¾À´Ê¹ÓÃRIA²â¶¨µÄÒ©Îï¶àÒѸÄÓÃÆäËûÃâÒß·ÖÎö·½·¨¡£Ó«¹âÆ«ÕñÃâÒ߲ⶨ·¨ÊÇ»ùÓÚ´ý²âÎïºÍÁª½ÓÁËÓ«¹âµÄ´ý²âÎï¶ÔÌØ¶¨µÄ´ý²âÎÌåÉÏÓÐÏÞµÄÊÜÌå½áºÏλµãµÄ¾ºÕùÐÔ½áºÏ¡£µ±´ý²âÑùÆ·ÖдæÔÚÄÜÓ뿹Ìå½áºÏµÄÒ©Îïʱ£¬½«ÐγÉÎÞÓ«¹âÒ©Îï-¿¹Ì帴ºÏÎ´Ó¶øÒýÆðÆ«Õñ¶ÈµÄϽµ£¬¸ù¾Ý¸ÃÆ«Õñ¶ÈϽµµÄ³Ì¶È¼´¿ÉÈ·¶¨³öÑùÆ·Öдý²âÎïµÄŨ¶È¡£¸Ã·¨ÁéÃô¶È¸ß£¬Ñ¡ÔñÐԺ㬵«È±µãÊÇÐèÒªÌØÊâµÄ¼ì²âÉ豸£¬¼Û¸ñ½ÏΪ°º¹ó£¬²Ù×÷Ò²²»Ì«·½±ã¡£Ã¸Ãâ·¨ÊÇÓÃø´úÌæÓ«¹âÌå±ê¼Ç¿¹Ô»ò¿¹Ì壬ÀûÓøÃøµÄµ×ÎïÏÔÉ«µÄ³Ì¶ÈÀ´È·¶¨ÑùÆ·ÖÐÒ©ÎïµÄŨ¶È¡£»¯Ñ§·¢¹âÃâÒß·ÖÎöÊǼÌÓ«¹â¡¢·ÅÉäÐÔÍ¬Î»ËØºÍøÃâ·ÖÎöÖ®ºó·¢Õ¹ÆðÀ´µÄÒ»ÏîеÄÃâÒß·ÖÎö¼¼Êõ£¬¸ù¾Ý´óÁ¿µÄʵÑé½á¹û¼°ÁÙ´²Ó¦ÓÃ×ÊÁÏ£¬´ÓʵÓÃÐÔ¡¢Îȶ¨ÐÔ¡¢×¼È·ÐÔ¡¢ÁéÃôÐÔ¼°·¢Õ¹Ç°¾°À´¿´£¬ÔÚ·Ç·ÅÉäÐÔ±ê¼Ç·ÖÎö¼¼ÊõÖл¯Ñ§·¢¹âÃâÒß·ÖÎö´¦ÓÚÁìÏȵØÎ»£¬´ú±íÁ˵±½ñÊÀ½ç·¢Õ¹µÄ·½ÏòºÍ³±Á÷£¬Ëü²»½ö¾ßÓÐÃâÒß·´Ó¦µÄÌØÒìÐÔ£¬¶øÇÒ¾ßÓл¯Ñ§·¢¹â·´Ó¦µÄ¸ßÁéÃô¶È£¬³ÉΪȡ´ú·ÅÉäÃâÒß·ÖÎöºÍøÃâÒß·ÖÎö¼¼ÊõµÄÊ×Ñ¡¡£»¯Ñ§·¢¹âÏÔÉ«µ×Îï¶Ô»¯Ñ§·¢¹âÃâÒß¼ì²âЧ¹û¾ßÓÐÖØÒªµÄÓ°Ï죬ֱ½ÓÓ°Ïì¼ì²âÊÔ¼ÁºÐµÄÁéÃô¶È¼°Îȶ¨ÐÔ£¬ºÃµÄ»¯Ñ§·¢¹âÏÔÉ«µ×ÎïÄÜʹ¼ì²âϵͳµÄ¼ì²âÏ޴ﵽƤ¿Ë¼¶£¬ÉõÖÁ¸ü¸ß£¬¶øÐ§¹ûÒ»°ãµÄ»¯Ñ§²»µ«ÁéÃô¶ÈµÍ£¬²»ÄÜÂú×ãÊÔÑéÒªÇ󣬶øÇÒÎȶ¨ÐÔ¼«²î£¬Ê¹µÃÿ´Î¼ì²â½á¹û²îÒ켫´ó£¬ÕâÑùÖ±½ÓÓ°Ï첡ÈËѪҩŨ¶ÈµÄ¼à²â½á¹û£¬µ¼ÖÂÒ½Éú²»Äܸù¾Ýÿ´Î¼ì²â½á¹û¶Ô²¡È˵ÄÓÃÒ©×ö³öÕýÈ·µÄÅжϡ£¶øÄ¿Ç°¹úÄÚÊÐÊÛ·¢¹âÏÔʾµ×ÎïÒºÓÃÓÚ°åʽµÄ»¯Ñ§·¢¹â¼ì²âÊÔ¼ÁºÐ£¬Æä·¢¹âÐÔÄܳ£³£´ï²»µ½¼ì²âÒªÇóµÄÁéÃôÐÔºÍÎȶ¨ÐÔ¡£
·¢Ã÷ÄÚÈÝ
±¾·¢Ã÷¸ù¾ÝÉÏÊöÁìÓòµÄÐèÇó¿Õ°×£¬ÌṩһÖÖÓÃÓÚ¼ì²âÈËȫѪÖÐËû¿ËĪ˾Ũ¶ÈµÄ»¯Ñ§·¢¹âøÁªÃâÒßÊÔ¼ÁºÐ£¬¼È¿ÉÒÔÓ¦ÓÃÓÚ¿ª·ÅʽµÄ°ë×Ô¶¯»¯Ñ§·¢¹â²âÁ¿ÒÇ£¬Ò²¿ÉÓÃÓÚÈ«×Ô¶¯µÄ²âÁ¿ÏµÍ³£¬ÊʺϹúÄÚÏÖ×´£¬³É±¾µÍ£¬µ«¼ì²âЧ¹ûÓë½ø¿ÚÊÔ¼ÁÎÞÏÔÖø²îÒì¿ÉʵÏÖ´óÅúÁ¿¿ìËÙ¼ì²â£¬¸üÒ×ÍÆ¹ãÓ¦Óá£Ò»ÖÖÓÃÓÚ»¯Ñ§·¢¹âøÁªÃâÒß¼ì²âµÄ»¯Ñ§·Å¹âµ×ÎïÏÔɫҺ£¬°üÀ¨Îªµ×ÎïAÒººÍµ×ÎïBÒº£¬ÆäÖÐAҺΪµÄ×é³ÉΪpHֵΪ7. 2 8. 5£¬Å¨¶ÈΪ0. 01 0. 03mol/LµÄÁ×ËáÑλº³åÒºÖмÓÈëÖÕŨ¶È(W/V)Ϊ0. 02 0. 05% Proclin300,1. 0 2. 0%ÍÂÎÂ-20ºÍ10mM/L ¹ýÑõ»¯ëåÈÜÒº£»BҺΪ50mM/LµÄ1Tris-HCI»º³åÒºÖмÓÈëÖÕŨ¶È(W/V)Ϊ0. 02 0. 05% Proclin300,0. 01 0. lmmol/L µÄËı½ÅðËáÑΣ¬0. 2 0. 6mmol/L µÄ 4-µâ±½·Ó£¬0.
µÄBSA£¬0. 1 µÄä廯ʮÁùÍé»ùÈý¼×»ùï§£¬10 50Mm/L³Ã×ŵÈÜÒº¡£Ò»ÖÖ¼ì²âÈËȫѪÖÐËû¿ËĪ˾ҩÎïŨ¶ÈµÄ»¯Ñ§·¢¹âøÁªÃâÒßÊÔ¼ÁºÐ£¬°üÀ¨»¯Ñ§·¢¹âø±ê°å£¬Ã¸±ê¼ÇÎËùÊö»¯Ñ§·¢¹âø±ê°åÉϵİü±»ÔΪ¿¹Ëû¿ËĪ˾µ¥¿Ë¡¿¹Ìå¡¢¶þ¿¹»òÓëÔØÌåµ°°×żÁªµÄËû¿ËĪ˾°ë¿¹Ô£»ÆäÌØÕ÷ÔÚÓÚ»¹°üÀ¨ÉÏÊö»¯Ñ§·¢¹âµ×ÎïÏÔɫҺ£¬ËùÊöø±ê¼ÇÎïΪÀ±¸ù¹ýÑõ»¯Îïø±ê¼ÇµÄ¿¹Ìå¡¢¿¹Ô»ò¿¹¿¹Ìå¡£ËùÊö°ü±»ÔΪËû¿ËĪ˾µ¥¿Ë¡¿¹Ì壬Ñò¿¹Ê󿹿¹Ìå»òÍÿ¹Ê󿹿¹Ì壬ËùÊöø±ê¼ÇÎïΪÀ±¸ù¹ýÑõ»¯Îïø±ê¼ÇµÄËû¿ËĪ˾°ë¿¹Ô¡£ËùÊö°ü±»ÔΪÑò¿¹Ê󿹿¹Ìå»òÍÿ¹Ê󿹿¹Ì壬ËùÊöø±ê¼ÇÎïΪÀ±¸ù¹ýÑõ»¯Îïø±ê¼ÇµÄËû¿ËĪ˾°ë¿¹Ô»òËû¿ËĪ˾µ¥¿Ë¡¿¹Ìå¡£ËùÊö°ü±»ÔΪÓëÔØÌåµ°°×żÁªµÄËû¿ËĪ˾°ë¿¹Ô£¬ËùÊöø±ê¼ÇÎïΪÀ±¸ù¹ýÑõ»¯Îïø±ê¼ÇµÄ¿¹Ëû¿ËĪ˾µ¥¿Ë¡¿¹Ìå¡£ËùÊöÔØÌåµ°°×Ϊ¼××´ÏÙµ°°×¡¢ÊóѪÇåµ°°×¡¢ÈËѪÇåµ°°×¡¢Å£ÑªÇåµ°°×¡¢ÍÃѪÇåµ°°×¡¢ À¶Ñªµ°°×»òÂÑÇåµ°°×¡£ËùÊöÊÔ¼ÁºÐ»¹°üÀ¨Ç°´¦ÀíÒº¡¢ÑùÆ·Ï¡ÊÍÒº¡¢Ëû¿ËĪ˾±ê׼ƷÈÜÒº¡¢Ëû¿ËĪ˾ÖÊÁ¿¿ØÖÆÈÜÒº¡¢Å¨ËõÏ´µÓÒº¡£ËùÊöÑùƷǰ´¦ÀíҺΪº¬20_100mMÁòËáпµÄ¼×´¼ÈÜÒºÓëÒÒ¶þ´¼»ìºÏÒº£¬¼×´¼ÓëÒÒ¶þ´¼µÄÌå»ý±È3 1¡£ËùÊöÑùÆ·Ï¡ÊÍҺΪº¬0. 3-0. 5M NaCLµÄ50mMµÄÁ×ËáÑλº³åÒº¡£Ëû¿ËĪ˾±ê׼ƷÈÜÒººÍÖÊÁ¿¿ØÖÆÆ·ÈÜҺΪº¬Óв»Í¬Å¨¶ÈËû¿ËĪ˾µÄÈËȫѪÈÜÒº¡£ËùÊöŨËõÏ´µÓÒºpHֵΪ7. 2 8. 5£¬º¬ÓÐÖÕŨ¶ÈΪ0. 02 0. 05% Proclin300, 1. 0 2. 0%ÍÂÎÂ-20ºÍ0. 01 0. 03mol/LµÄÁ×ËáÑλº³åÒº¡£ ±¾·¢Ã÷½«»¯Ñ§·¢¹â¼¼ÊõÓëËû¿ËĪ˾µÄÃâÒß·ÖÎö·¨ÓÐЧµÄ½áºÏ£¬²ÉÓÃÁË×ÔÖÆµÄ·¢¹âÐźÅÇ¿¡¢³ÖÐøÊ±¼ä³¤¡¢¸ü¸ßÐÅÔë±ÈµÄ»¯Ñ§·¢¹âµ×ÎïÏÔɫҺ£¬Óë½ø¿ÚÊÔ¼ÁºÐ¼ì²âЧ¹û¼¸ºõÎÞ²î±ð£¬¼ì²âЧ¹ûÃ÷ÏÔÓÅÓÚ¹ú²úÊÔ¼ÁºÐ£¬¶ø¼Û¸ñÉÏÃ÷ÏÔµÍÓÚ½ø¿ÚÊÔ¼ÁºÐ£¬Îª¹úÄÚ»¼ÕßËùÄܳÐÊÜ£¬ ¶Ô¹úÄÚÆ÷¹ÙÒÆÖ²»¼Õß¾ßÓÐÖØ´óÒâÒå¡£ÁíÍâ±¾·¢Ã÷µÄÊÔ¼ÁºÐ²ÉÓÃÁË»¯Ñ§·¢¹âøÁªÃâÒß·½·¨£¬ ±ÈøÃâÒß·ÖÎö·¨ÁéÃô¶È¸ß£¬Äܹ»¼ò±ã¡¢¿ìËÙ¡¢ÁéÃô¡¢Îȶ¨µÄ¼ì²âѪÖÐËû¿ËĪ˾ҩÎïŨ¶È¡£±¾·¢Ã÷µÄ¼ì²âÈËȫѪÖÐËû¿ËĪ˾ҩÎïŨ¶ÈµÄ»¯Ñ§·¢¹â·¨Ã¸ÁªÃâÒßÊÔ¼ÁºÐÖ÷Òª²ÉÓÃÖ±½Ó¾ºÕùELISA·½·¨¶¨Á¿¼ì²âÑùÆ·ÖÐËû¿ËĪ˾µÄŨ¶È¡£±¾ÊÔ¼ÁºÐÖвÉÓøßÌØÒìÐÔµÄËû¿ËĪ˾µÄµ¥¿Ë¡¿¹Ì壬±£Ö¤Á˼ì²â½á¹ûµÄ¿É¿¿ÐÔ¡£ÊµÑé½á¹û±íÃ÷£¬±¾ÊÔ¼ÁºÐ¾ßÓÐÌØÒìÐԸߡ¢ÁéÃô¶È¸ü¸ß¡¢¾«È·¶È¸ß¡¢×¼È·¶È¸ßµÈÌØµã¡£±¾ÊÔ¼ÁºÐµÄÖ÷ÒªÊÔ¼Á¶¼²ÉÓù¤×÷ÒºÐÎʽ£¬Ê¹Ó÷½±ã£¬ ³É±¾µÍÁ®¡£Óñ¾·¢Ã÷ÊÔ¼ÁºÐ¼ì²âËû¿ËĪ˾µÄ·½·¨£¬²Ù×÷¼ò±ã£¬¼ò»¯ÁË´«Í³¼ì²â·½·¨µÄ²½Ö裬 Ëõ¶ÌÁ˼ì²âʱ¼ä£¬¶ÔÑùÆ·µÄǰ´¦ÀíÒªÇóµÍ£¬ÄÜͬʱ¿ìËÙ¼ì²â´óÅúÁ¿µÄÑùÆ·¡£ÊÔÑé½á¹ûÖ¤Ã÷£¬ ±¾·¢Ã÷µÄÊÔ¼ÁºÐ
ͼ1Ϊ°ü±»ÔΪËû¿ËĪ˾µÄµ¥¿Ë¡¿¹ÌåµÄ¼ì²âÊÔ¼ÁºÐµÄ±ê×¼ÇúÏß¡£Í¼2·¢¹âµ×Îï±È½ÏʵÑé¡£´ÓÉÏÍùÏÂÒÀ´ÎΪ½ø¿Ú·¢¹âµ×Î±¾·¢Ã÷µÄ·¢¹âµ×Î¹úÄÚÏÖÓз¢¹âµ×Îï¡£¹úÄÚÏÖÓз¢¹âµ×ÎïÃ÷ÏÔµÍÓÚ±¾·¢Ã÷µÄ²úÆ·£¬¶ø±¾·¢Ã÷µÄ²úÆ·Óë½ø¿Ú·¢¹âµ×ÎïÖ®¼äÎÞÌ«´ó²î¾à¡£
¾ßÌåʵʩÀý·½Ê½ÏÂÊöʵʩÀýÖÐËùʹÓõÄʵÑé·½·¨ÈçÎÞÌØÊâ˵Ã÷£¬¾ùΪ³£¹æ·½·¨¡£ÊµÊ©Àý1¡¢Ëû¿ËĪ˾µ¥¿Ë¡¿¹ÌåΪ°ü±»Ô£¬±ê¼ÇÎïΪø±ê°ë¿¹ÔµÄÊÔ¼ÁºÐÖÆ±¸¼°Ê¹Ó᪡¢ÒÔËû¿ËĪ˾µ¥¿Ë¡¿¹ÌåΪ°ü±»Ô¡¢Ã¸±ê¼ÇËû¿ËĪ˾°ë¿¹ÔΪ±ê¼ÇÎïµÄÊÔ¼ÁºÐ¼ì²âÔÀíÈçÏÂÔÚ΢¿×ÌõÉÏÔ¤°ü±»Ëû¿ËĪ˾µ¥¿Ë¡¿¹Ì壬Ñù±¾ÖеÄËû¿ËĪ˾Óëø±ê¼ÇµÄËû¿ËĪ˾Óë΢¿×ÌõÉÏÔ¤°ü±»µÄ¿¹Ëû¿ËĪ˾¿¹Ìå½øÐоºÕùÐÔ½áºÏ£¬ÕâÑù£¬Ñù±¾Îü¹âÖµÓëÆäÑù±¾ÖÐËùº¬Ëû¿ËĪ˾µÄº¬Á¿³É¸ºÏà¹Ø£¬Óë±ê×¼ÇúÏ߱Ƚϼ´¿ÉµÃ³öÑù±¾ÖÐËû¿ËĪ˾µÄÁ¿¡£¶þ¡¢ÊÔ¼ÁºÐ×é³ÉIºÅÊÔ¼ÁºÐ1¡¢°ü±»Óаü±»ÔµÄ»¯Ñ§·¢¹âø±ê°å°ü±»ÔΪ¿¹Ëû¿ËĪ˾µÄÊóÔ´µ¥¿Ë¡¿¹Ì壬°ü±»Å¨¶È¿ÉÒÔΪ0. 1-lOng/ml¡£2¡¢Ã¸±ê¼Ç°ë¿¹ÔΪÀ±¸ù¹ýÑõ»¯Îïø±ê¼ÇµÄËû¿ËĪ˾°ë¿¹Ô£¬Æä¹¤×÷Ï¡ÊͶÈΪ 1 3000¡£3¡¢Ëû¿ËĪ˾±ê׼ƷÈÜÒº6Æ¿£¬2ml/Æ¿£¬Å¨¶È·Ö±ðΪ0ng/ml¡¢3ng/ml¡¢6ng/ml¡¢12ng/ ml¡¢ 20ng/ml¡¢30ng/mlo4¡¢Ëû¿ËĪ˾ÖÊÁ¿¿ØÖÆÒº2Æ¿£¬2ml/Æ¿£¬Å¨¶È·Ö±ðΪ5ng/ml¡¢25ng/ml¡£5¡¢ÑùÆ·Ï¡ÊÍҺΪº¬0. 3M NaCLµÄ50mMµÄÁ×ËáÑλº³åÒº£¬20ml/Æ¿£¬1Æ¿6¡¢»¯Ñ§·¢¹âµ×ÎïÏÔɫҺAÒººÍBÒº¸÷1Æ¿£¬ÆäÖÐAҺΪµÄ×é³ÉΪpHֵΪ8. 0£¬ Ũ¶ÈΪIOmMµÄÁ×ËáÑλº³åÒºÖмÓÈëÖÕŨ¶È(V/V)Ϊ0. 02% Proclin300,1. 0%ÍÂÎÂ-20 ºÍIOmM¹ýÑõ»¯ëåÈÜÒº£»BҺΪ50mMµÄ1Tris-HCI»º³åÒºÖмÓÈëÖÕŨ¶È(W/V)Ϊ0. 02 % ft~OClin300£¬2mMµÄ4-µâ±½·Ó£¬0. µÄBSA£¬0. 1 %µÄä廯ʮÁùÍé»ùÈý¼×»ùï§£¬IOMm³Ã×ŵÈÜÒº¡£7¡¢Å¨ËõÏ´µÓÒºpHֵΪ7. 4£¬º¬ÓÐÔÚËùÊöŨËõÏ´µÓÒºÖеÄÖÕŨ¶ÈΪ0.05% PrOclin300¡¢ÔÚËùÊöŨËõÏ´µÓÒºÖеÄÖÕŨ¶ÈΪ2. 0%ÍÂÎÂ_20¡¢0. 02mol/LµÄÁ×ËáÑλº³åÒº£¬ 40ml/Æ¿£¬1 Æ¿¡£8¡¢ÑùÆ·´¦ÀíҺΪº¬20_100mMÁòËáпµÄ¼×´¼ÈÜÒºÓëÒÒ¶þ´¼»ìºÏÒº£¬IOml/Æ¿£¬1Æ¿¡£IIºÅÊÔ¼ÁºÐÆäËüͬIºÅ£¬½ö»¯Ñ§·´¹âµ×ÎïÏÔɫҺ³É·ÖÓиıä:AÒººÍBÒº¸÷1Æ¿£¬ÆäÖÐAҺΪµÄ×é³ÉΪPHֵΪ8.0£¬Å¨¶ÈΪ30mMµÄÁ×ËáÑλº³åÒºÖмÓÈëÖÕŨ¶È(V/V)Ϊ0. 05 % Proclin300,0. 5%ÍÂÎÂ-20ºÍIOmM¹ýÑõ»¯ëåÈÜÒº£»BҺΪ50mMµÄTris-HCI»º³åÒºÖмÓÈëÖÕŨ¶È(W/¦Í)Ϊ0. 05% Proclin300, 3mMµÄ4-µâ±½·Ó£¬1 %µÄBSA£¬1 %µÄä廯ʮÁùÍé»ùÈý¼×»ùï§£¬50mM³Ã×ŵÈÜÒº¡£IIIºÅÊÔ¼ÁºÐÆäËüͬIºÅ£¬½ö»¯Ñ§·´¹âµ×ÎïÏÔɫҺ³É·ÖÓиıä:AÒººÍBÒº¸÷1Æ¿£¬ÆäÖÐAҺΪµÄ×é³ÉΪPHֵΪ8.0£¬Å¨¶ÈΪ20mMµÄÁ×ËáÑλº³åÒºÖмÓÈëÖÕŨ¶È(V/V)Ϊ0. 04 % Proclin300,0. ÍÂÎÂ-20ºÍIOmM¹ýÑõ»¯ëåÈÜÒº£»BҺΪ50mMµÄTris-HCI»º³åÒºÖмÓÈëÖÕŨ¶È(W/¦Í)Ϊ0. 04% Proclin300£¬2mMµÄ4-µâ±½·Ó£¬0. 7%µÄBSA, 0. 4%µÄä廯ʮÁùÍé»ùÈý¼×»ùï§£¬30mM³Ã×ŵÈÜÒº¡£¶ÔÕÕÊÔ¼ÁºÐÆäËüͬIºÅÊÔ¼ÁºÐ£¬¶ø»¯Ñ§·´¹âµ×ÎïÏÔɫҺΪÊÐÊÛÏÔɫҺ(AҺΪ¹ýÑõ»¯ëåÈÜÒº£¬BҺΪ³Ã×ŵÈÜÒº£¬¹º×ÔºþÖÝÓ¢´´ÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾)¡£
Èý¡¢ÖƱ¸·½·¨1¡¢°ü±»ÓÐËû¿ËĪ˾µ¥¿Ë¡¿¹ÌåµÄ»¯Ñ§·¢¹âø±ê°åµÄÖÆ±¸(1)Ëû¿ËĪ˾µ¥¿Ë¡¿¹ÌåÑ¡ÔñFitzgerald¹«Ë¾Éú²úµÄËû¿ËĪ˾µ¥¿Ë¡¿¹Ìåmouse monoclonal anti-tacrolimus antibody, IgM0(2)°ü±»Óаü±»ÔµÄ»¯Ñ§·¢¹âø±ê°åµÄÖÆ±¸Óðü±»»º³åÒº(pHֵΪ9. 6,0. lmol/L̼ËáÑλº³åÒº)½«ÒÔÉÏËû¿ËĪ˾¿¹Ìå½øÐÐ 1 8000Ï¡ÊÍ£¬¼ÓÈëµ½»¯Ñ§·¢¹âø±ê°å¿×ÖУ¬Ã¿¿×100¦Ì 1£¬37¡ãC·´Ó¦2Сʱ£¬Ë¦µô°ü±»Òººó£¬ Åĸɣ¬Ã¿¿×¼ÓÈë200 ¦Ì 1µÄ·â±ÕÒº(º¬ÖÕŨ¶ÈΪ2%ţѪÇå°×µ°°×Á×ËáÑλº³åÒº)£¬37¡ãC·´Ó¦ 2Сʱ£¬Ë¦µô·â±ÕÒº£¬Åĸɣ¬×ÔÈ»ÁÀ¸É£¬ÓÃÂÁ²´üÕæ¿Õ°ü×°±£´æ¡£2¡¢Ã¸±ê°ë¿¹ÔµÄÖÆ±¸(1)°ë¿¹ÔµÄÖÆ±¸×¼È·³ÆÈ¡250mgËû¿ËĪ˾£¬18mgçúçêËáôû£¬6mgà×à¤ÈܽâÓÚ6. 3ml ¶þÂȼ×ÍéÖУ¬±ß½Á°è±ß¼ÓÈë42ulÈýÒÒ°·£¬ÔÚÊÒÎÂϼÌÐø½Á°è2Сʱ£¬È»ºóÓöþÂȼ×ÍéÏ¡ÊÍÖÁ20ml£¬ÔÙ·Ö±ðÓõÈÁ¿µÄ0. 1µ±Á¿ÑÎËá¡¢´¿»¯Ë®¡¢±¥ºÍµÄÂÈ»¯ÄƸ÷Ï´µÓÒ»´ÎºóÓ÷ÖҺ©¶·¾²Ö¹·Ö²ã£¬¹ýÂËÊÕ¼¯Ï²ãÒº(¶þÂȼ×Íé)¡£ËùµÃµ½µÄÓлúÏà·ÅÔÚÎÞË®ÁòËáþ½øÐиÉÔÓôÅÁ¦½Á°èÆ÷½Á°è30 ·ÖÖӺ󣬳ýµôÁòËáþ£¬ÓÃÐýתÕô·¢ÒÇŨËõ£¬Ö±ÖÁ³ÊÇá΢»ÆÉ«ÅÝÄ¡£ÔÚÐýתÕô·¢ÒÇÉϽ«ÉÏÊöÈÜÒº½øÐиÉÔµÃµ½Ëû¿ËĪ˾°ëçúÖéËáõ¥¡£³ÆÈ¡35mgÉÏÊö²úÎ5. 4mgN-ôÇ»ùçúçêõ£Ñǰ·ºÍ8. 8mgN, N- ¶þ»·¼º»ù̼»¯¶þÑǰ·ÈÜÓÚ5mlÒÒËáÒÒõ¥£¬ÔÚ´ÅÁ¦½Á°èÆ÷ÉϼÌÐø½Á°èMСʱ¡£ 6000rpmÀëÐÄ5·ÖÖÓ£¬È¡ÉÏÇ屸Óá£(2)ÓÃÀ±¸ù¹ýÑõÎïø¶ÔÉÏÊö°ë¿¹Ô½øÐбê¼Ç³ÆÈ¡ImgÉÏÊö°ë¿¹ÔÈÜÓÚaiil N, N- ¶þ¼×»ù¼×õ£°·£¬ÊÒνÁ°è30min£¬ÖðµÎ¼ÓÈëµ½ IOml (º¬5mg)µÄÀ±¸ù¹ýÑõ»¯ÎïøÈÜÒºÖУ¬ÊÒνÁ°è¹ýÒ¹ºó£¬ÓÃkphadex G-25½øÐвãÎö´¿»¯¡£ÊµÊ©Àý2.ÒÔËû¿ËĪ˾µ¥¿Ë¡¿¹ÌåΪ°ü±»Ô¡¢Ã¸±ê¼Ç°ë¿¹ÔΪ±ê¼ÇÎïµÄÊÔ¼ÁºÐµÄÓ¦Óñ¾·¢Ã÷ÊÔ¼ÁºÐÓÃÓÚ¶¨Á¿¼ì²âÈËȫѪÖÐËû¿ËĪ˾µÄÒ©ÎïŨ¶È¡£1¡¢ÈËȫѪÑùÆ·µÄǰ´¦Àí½«2_8¡ãC±ùÏä±£´æµÄÈËȫѪËû¿ËĪ˾±ê׼Ʒ¼°ÖÊÁ¿¿ØÖÆÆ·ÈÜÒººÍ´ý¼ìÑùÆ·£¬ÔÚÕñµ´Æ÷Éϳä·ÖÕñµ´»ì„ò£¬Á¢¼´¾«È·ÎüÈ¡150¦Ì 1ÿ¸öÑùÆ·µ½ÏàÓ¦µÄÀëÐĹÜÖУ¬¼ÓÈëµÈÌå»ýµÄÑùƷǰ´¦ÀíÒººóÁ¢¼´¸ÇºÃ¹Ü¸Ç£¬ÓÃäöÎлìºÏÒǸßËÙÐýת£¬È·±£Ã¿¸öÑùÆ·³ä·Ö»ì„ò£¬½«ÀëÐĹܷÅÈëÀëÐÄ»ú£¬13000r/min£¬ÀëÐÄ6·ÖÖÓ¡£È¡20 ¦Ì 1ÓÃÓÚ·ÖÎö¡£2¡¢¼ì²âÏòIIºÅÊÔ¼ÁºÐµÄ»¯Ñ§·¢¹âø±ê°åÖмÓÈëÑùÆ·Ï¡ÊÍÒº30¦Ì 1£¬È»ºóÔÚÿ¿×ÖмÓÈëËû¿ËĪ˾±ê׼ƷÈÜÒº¡¢ÖÊÁ¿¿ØÖÆÆ·ÈÜÒº¼°ÑùÆ·ÈÜÒº20 ¦Ì 1£¬Ã¿¿×Öи÷¼ÓÈëÀ±¸ù¹ýÑõ»¯Îïø±ê¼ÇµÄ°ë¿¹Ô50 ¦Ì 1£¬ÓøǰåÄ£·â°å£¬37¡ãCºãÎÂÏäÖз´Ó¦1Сʱ£¬Ë¦¸É¿×ÄÚÒºÌ壬ϴ°å5´Î£¬Åĸɣ» ÿ¿×¼ÓÈëµ×ÎïÏÔɫҺAÒº¹ýÑõ»¯ë壬µ×ÎïÏÔɫҺBҺ³Ã×ŵ£¬ÇáÇáÕñµ´»ì„ò£¬ÔÚ2-5minÄÚ£¬ Óû¯Ñ§·¢¹âÒÇ£¬²â¶¨Ã¿¿×·¢¹âÖµ(RULÖµ)¡£3¡¢¼ì²â½á¹û·ÖÎöÒÔ±ê׼ƷŨ¶È±êʾֵΪXÖᣬÒÔ¼ì²â·¢¹âֵΪYÖᣬ½øÐÐËIJÎÊýÄâºÏ£¬µÃµ½»Ø¹é·½³Ì¼°ÄâºÏÇúÏßͼ1¡£½«´ý¼ì²âÑùÆ·Îü¹â¶È´øÈë»Ø¹é·½³Ì£¬¼´¿ÉÇóµÃÑùƷŨ¶È¡£±¾·¢Ã÷Öмì²â½á¹ûµÄ·ÖÎö»¹¿ÉÒÔÀûÓüÆËã»úרҵÈí¼þ£¬´Ë·¨¸ü±ãÓÚ´óÁ¿ÑùÆ·µÄ¿ìËÙ·ÖÎö¡£4¡¢ÊÔ¼ÁºÐÁéÃô¶È¡¢¾«Ãܶȡ¢×¼È·¶ÈºÍ±£´æÆÚ¼ì²â(1)±ê׼Ʒ¾«ÃܶÈÊÔÑé´ÓʵʩÀý1²½ÖèÈýÖÆ±¸µÄͬһÐͺÅ(IIºÅ)ÊÔ¼ÁºÐµÄ²»Í¬Åú´Î(01Åú¡¢02Åú¡¢03 Åú)µÄÊÔ¼ÁºÐÖи÷³éÈ¡10¸öÊÔ¼ÁºÐ£¬´Óÿ¸öÊÔ¼ÁºÐµÄ»¯Ñ§·¢¹âø±ê°åÖи÷³é³ö20¸ö΢¿×£¬ ²â¶¨20ng/mlËû¿ËĪ˾±ê×¼ÈÜÒºµÄÎü¹âÖµ(0DÖµ)£¬¼ÆËã±äÒìϵÊýCV%¡£ÊµÑé½á¹ûÈç±í1Ëùʾ£¬±ê׼ƷÎü¹âÖµµÄ±äÒìϵÊýÔÚ5. 46% -15. 08%Ö®¼ä£¬·ûºÏ¾«ÃܶÈСÓÚ»òÕßµÈÓÚ20%µÄ¹æ¶¨¡£±í1±ê×¼Æ·ÖØ¸´ÐÔÊÔÑé(CV % )
ȨÀûÒªÇó
1.ÓÃÓÚ»¯Ñ§·¢¹âøÁªÃâÒß¼ì²âµÄ»¯Ñ§·Å¹âµ×ÎïÏÔɫҺ£¬°üÀ¨Îªµ×ÎïAÒººÍµ×ÎïBÒº£¬ ÆäÖÐAҺΪµÄ×é³ÉΪpHֵΪ7. 2 8. 5£¬Å¨¶ÈΪ10 30mMµÄÁ×ËáÑλº³åÒºÖмÓÈëÖÕŨ¶È (V/V)Ϊ0. 02 0. Proclin300,0. 1 1. 0%ÍÂÎÂ-20ºÌ¦° IOmM¹ýÑõ»¯ëåÈÜÒº£»BҺΪ 50mM µÄ Tris-HCI »º³åÒºÖмÓÈëÖÕŨ¶È(W/V)Ϊ 0. 02 0. 1 % Proclin300,1. 0 3. OmM µÄ4-µâ±½·Ó£¬0. µÄBSA£¬0. 1 µÄä廯ʮÁùÍé»ùÈý¼×»ùï§£¬10 50mM³Ã×ŵÈÜÒº¡£
2.¼ì²âÈËȫѪÖÐËû¿ËĪ˾ҩÎïŨ¶ÈµÄ»¯Ñ§·¢¹âøÁªÃâÒßÊÔ¼ÁºÐ£¬°üÀ¨»¯Ñ§·¢¹âø±ê°å£¬Ã¸±ê¼ÇÎËùÊö»¯Ñ§·¢¹âø±ê°åÉϵİü±»ÔΪ¿¹Ëû¿ËĪ˾µ¥¿Ë¡¿¹Ìå¡¢¶þ¿¹»òÓëÔØÌåµ°°×żÁªµÄËû¿ËĪ˾°ë¿¹Ô£»ÆäÌØÕ÷ÔÚÓÚ»¹°üÀ¨È¨ÀûÒªÇó1ËùÊöµÄ»¯Ñ§·¢¹âµ×ÎïÏÔɫҺ£¬ËùÊöø±ê¼ÇÎïΪÀ±¸ù¹ýÑõ»¯Îïø±ê¼ÇµÄ¿¹Ìå¡¢¿¹Ô»ò¿¹¿¹Ìå¡£
3.¸ù¾ÝȨÀûÒªÇó2ËùÊöµÄ»¯Ñ§·¢¹âøÁªÃâÒßÊÔ¼ÁºÐ£¬ËùÊö°ü±»ÔΪËû¿ËĪ˾µ¥¿Ë¡¿¹Ì壬Ñò¿¹Ê󿹿¹Ìå»òÍÿ¹Ê󿹿¹Ì壬ËùÊöø±ê¼ÇÎïΪÀ±¸ù¹ýÑõ»¯Îïø±ê¼ÇµÄËû¿ËĪ˾°ë¿¹Ô¡£
4.¸ù¾ÝȨÀûÒªÇó2ËùÊöµÄ»¯Ñ§·¢¹âøÁªÃâÒßÊÔ¼ÁºÐ£¬ËùÊö°ü±»ÔΪÑò¿¹Ê󿹿¹Ìå»òÍÿ¹Ê󿹿¹Ì壬ËùÊöø±ê¼ÇÎïΪÀ±¸ù¹ýÑõ»¯Îïø±ê¼ÇµÄËû¿ËĪ˾°ë¿¹Ô»òËû¿ËĪ˾µ¥¿Ë¡¿¹Ìå¡£
5.¸ù¾ÝȨÀûÒªÇó2ËùÊöµÄ»¯Ñ§·¢¹âøÁªÃâÒßÊÔ¼ÁºÐ£¬ËùÊö°ü±»ÔΪÓëÔØÌåµ°°×żÁªµÄËû¿ËĪ˾°ë¿¹Ô£¬ËùÊöø±ê¼ÇÎïΪÀ±¸ù¹ýÑõ»¯Îïø±ê¼ÇµÄ¿¹Ëû¿ËĪ˾µ¥¿Ë¡¿¹Ìå¡£
6.¸ù¾ÝȨÀûÒªÇó2 5ÈÎÒ»ËùÊöµÄ»¯Ñ§·¢¹âøÁªÃâÒßÊÔ¼ÁºÐ£¬ËùÊöÔØÌåµ°°×Ϊ¼××´ÏÙµ°°×¡¢ÊóѪÇåµ°°×¡¢ÈËѪÇåµ°°×¡¢Å£ÑªÇåµ°°×¡¢ÍÃѪÇåµ°°×¡¢À¶Ñªµ°°×»òÂÑÇåµ°°×¡£
7.¸ù¾ÝȨÀûÒªÇó6ËùÊöµÄ»¯Ñ§·¢¹âøÁªÃâÒßÊÔ¼ÁºÐ£¬ËùÊöÊÔ¼ÁºÐ»¹°üÀ¨Ç°´¦ÀíÒº¡¢ÑùÆ·Ï¡ÊÍÒº¡¢Ëû¿ËĪ˾±ê׼ƷÈÜÒº¡¢Ëû¿ËĪ˾ÖÊÁ¿¿ØÖÆÈÜÒº¡¢Å¨ËõÏ´µÓÒº¡£
8.¸ù¾ÝȨÀûÒªÇó7ËùÊöµÄ»¯Ñ§·¢¹âøÁªÃâÒßÊÔ¼ÁºÐ£¬ËùÊöÑùƷǰ´¦ÀíҺΪº¬20-100mM ÁòËáпµÄ¼×´¼ÈÜÒºÓëÒÒ¶þ´¼»ìºÏÒº£¬¼×´¼ÓëÒÒ¶þ´¼µÄÌå»ý±È3 1¡£
9.¸ù¾ÝȨÀûÒªÇó7ËùÊöµÄ»¯Ñ§·¢¹âøÁªÃâÒßÊÔ¼ÁºÐ£¬ËùÊöÑùÆ·Ï¡ÊÍҺΪº¬0.3-0. 5M NaCLµÄ50mMµÄÁ×ËáÑλº³åÒº¡£
10.¸ù¾ÝȨÀûÒªÇó7ËùÊöµÄ»¯Ñ§·¢¹âøÁªÃâÒßÊÔ¼ÁºÐ£¬ËùÊöŨËõÏ´µÓÒºpHֵΪ7.2 8. 5£¬º¬ÓÐÖÕŨ¶ÈΪ 0. 02 0. 05% Proclin300,1. 0 2. 0%ÍÂÎÂ-20 ºÍ 0. 01 0. 03mol/ LµÄÁ×ËáÑλº³åÒº¡£
È«ÎÄÕªÒª
±¾·¢Ã÷¡°¼ì²âÈËȫѪÖÐËû¿ËĪ˾ҩÎïŨ¶ÈµÄ»¯Ñ§·¢¹âøÁªÃâÒßÊÔ¼ÁºÐ¡±£¬ÊôÓÚҽѧ¼ì²âÊÔ¼Á£¬°üÀ¨»¯Ñ§·¢¹âø±ê°å£¬Ã¸±ê¼ÇÎËùÊö»¯Ñ§·¢¹âø±ê°åÉϵİü±»ÔΪ¿¹Ëû¿ËĪ˾µ¥¿Ë¡¿¹Ìå¡¢¶þ¿¹»òÓëÔØÌåµ°°×żÁªµÄËû¿ËĪ˾°ë¿¹Ô£»ÆäÌØÕ÷ÔÚÓÚ»¹°üÀ¨×ÔÖÆµÄʹÊÔ¼ÁºÐ¾ßÓиü¸ßÐÅÔë±È£¬¼ì²âÁéÃô¶ÈµÄ»¯Ñ§·¢¹âµ×ÎïÏÔɫҺ£¬ËùÊöø±ê¼ÇÎïΪÀ±¸ù¹ýÑõ»¯Îïø±ê¼ÇµÄ¿¹Ìå¡¢¿¹Ô»ò¿¹¿¹Ìå¡£¼È¿ÉÒÔÓ¦ÓÃÓÚ¿ª·ÅʽµÄ°ë×Ô¶¯»¯Ñ§·¢¹â²âÁ¿ÒÇ£¬Ò²¿ÉÓÃÓÚÈ«×Ô¶¯µÄ²âÁ¿ÏµÍ³£¬ÊʺϹúÄÚÏÖ×´£¬³É±¾µÍ£¬µ«¼ì²âЧ¹ûÓë½ø¿ÚÊÔ¼ÁÎÞÏÔÖø²îÒì¿ÉʵÏÖ´óÅúÁ¿¿ìËÙ¼ì²â£¬¸üÒ×ÍÆ¹ãÓ¦Óá£
Îĵµ±àºÅG01N21/76GK102368054SQ20111018327
¹«¿ªÈÕ2012Äê3ÔÂ7ÈÕ ÉêÇëÈÕÆÚ2011Äê6ÔÂ30ÈÕ ÓÅÏÈȨÈÕ2011Äê6ÔÂ30ÈÕ
·¢Ã÷ÕßÀîÈ«, ½¹ÊØË¡, ¼Ö·ïÇÛ ÉêÇëÈË:ͬê¿ÉúÎï¼¼Êõ(±±¾©)ÓÐÏÞ¹«Ë¾